Chinese medicine industry has a lot to offer a number of public offering is the layout of Chinese medicine ETF

In recent years, Chinese medicine-related favorable policies have been continuously introduced, and the Chinese medicine industry has ushered in a period of development dividends. As an important part of institutional investors, many fund companies are also intensively distributing traditional Chinese medicine theme products, especially index funds.

Regarding the reasons for the active layout of products related to the Chinese medicine track, a number of fund companies told the "Securities Daily" reporter that one is optimistic about the investment value of the Chinese medicine industry, and the other is to provide convenient investment channels for ordinary investors to participate in the Chinese medicine track. This yearSince June, Wells Fargo, China Merchants, and China Universal Fund have applied for Chinese medicine ETF products that track the China Securities Traditional Chinese Medicine Index. Prior to this, companies such as Huatai Berry Fund, Penghua Fund, and Yinhua Fund have applied for related products. If the above products are finally Approved, the first batch of Chinese medicine ETF funds will be officially launched.

Talking about the declaration of traditional Chinese medicine by fund companiesThe reason for ETF products, Xu Rongman, manager of China Merchants National Securities Biopharmaceutical Fund, told the Securities Daily reporter, "It is mainly due to the relative scarcity of Chinese medicine-related products in the current market, and the Chinese medicine industry has a development logic that is different from other pharmaceutical segments."

Lu Na, manager of Hang Seng Qianhai Consumption Upgrade Hybrid Fund and chief of pharmaceutical research, also told the Securities Daily reporter,"Benefiting from favorable policies, the Chinese medicine industry has further expanded, and the related investment value is very prominent. This is also a number of public funds applying for Chinese medicineThe main reason for the ETF.""If the traditional Chinese medicineThe approval of ETF products has two major benefits for investors. One is to reduce the difficulty of investing in the Chinese medicine industry. The Chinese medicine industry is a knowledge-and technology-intensive industry with high professionalism, rapid industry development, long industrial chain extension, and complex industry segmentation. The second is to diversify investment risk. ETF products are less volatile than individual stocks."

"However, the pharmaceutical industry as a whole is highly professional, the industry is updated and developed rapidly, and the differentiation of different sub-tracks is also obvious. Investors need to carefully identify the specific investment direction of products when investing in relevant varieties. At the same time, they can pay more attention to the industry and the relevant dynamics of core enterprises." Xu Rongman told reporters.

Looking forward to the future development of the Chinese medicine sector, Zhang Yuxiang, fund manager of the Penghua Fund Quantitative and Derivatives Investment Department, told a reporter from the Securities Daily,"prior to this, the chinese medicine plate went through a period of confusion and difficulties,2022 is expected to usher in a reversal; in recent years, the state has strongly supported the development of Chinese medicine, the relevant policies have been introduced, in the context of the valuation correction of the overall pharmaceutical sector, the Chinese medicine sector as an undervalued sector, is expected to usher in valuation remodeling; it is expected that this round of Chinese medicine market has medium-and long-term sustainability. Chinese medicine has the properties of consumer goods and health care products. At present, driven by the increasing demand for medical and health care among the middle-aged and elderly people and the upgrading of residents' consumption, the traditional Chinese medicine industry continues to develop, and the traditional Chinese medicine industry has a bright future."